New data from RAD 2023 revealed the results of assessing the independent and combined effects of itch and skin severity on patient-reported symptoms and QoL.
According to a poster presentation from the 2023 Revolutionizing Atopic Dermatitis conference in Washington, DC, complete or almost complete relief of both itch and skin lesions is associated with an increased chance of achieving ideal states in patient-reported outcomes (PROs) and the Dermatology Life Quality Index (DLQI).1
Silverberg et al sought to investigate and understand the combined impact of itch and skin severity on patient-reported symptoms and quality of life outcomes in patients with atopic dermatitis, as they noted there is limited evidence examining the combined impact.
Adult patients 18 years or older were enrolled in TARGET-DERM AD, an observational, longitudinal study of patients with atopic dermatitis across 43 academic/community centers in the United States and Canada (n=3158). The longitudinal study used the following assessments to evaluate itch and skin severity:
Out of the 3158 patients enrolled in TARGET-DERM AD, 1795 were adults and 792 had baseline POEM scores and 783 had baseline 783 DLQI scores. Results from the analyses included:
Silverberg et al concluded from their findings that the results demonstrate the importance of assessing and documenting both itch severity and skin clearance to encourage shared decision making and setting achievable treatment goals. The investigators also noted that “future research should include analyzing discrepant data (e.g., patients with no/minimal itch, but some skin lesions) to more precisely identify which aspect drives the patient-reported outcomes.”